Algernon Pharmaceuticals Inc (AGNPF)

[medchem]

Many drugs failing:

Remdisivir failed according to the WHO in leaked documents (posts from a day or two ago). Now there is a new study published in the top medical journl NEJM which shows that Lopinavir and Ritonavir (the next "most likely to work" medications) have failed.

https://www.ncbi.nlm.nih.gov/pubmed/?term=A+trial+of+lopinavir-ritonavir+in+adults+hospitalized+with+severe+COVID-19.+N+Engl+J+Med+2020

In this open-label trial, researchers in Wuhan enrolled patients hospitalized with COVID-19 and oxygen saturation of 94% or less on room air. They randomized the patients to receive standard care (n = 100) or standard care plus an HIV-medication called lopinavir-ritonavir (Kaletra; 400 mg/ 100 mg; n = 99) twice a day for 14 days. They found no statistically significant difference in the duration of illness. Although the patients treated with lopinavir-ritonavir had 5.8% fewer deaths, this was not statistically significant. But in order to detect this difference a study would need more than 800 patients in each group. Stay tuned - hopefully, this will be studied further.

Bottom line

A randomized trial of 199 patients found no evidence of benefit for lopinavir-ritonavir in patients with COVID-19.